Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that participants with HR-positive/HER2-negative advanced or metastatic breast cancer treated with sacituzumab govitecan had better quality of life and longer survival compared to standard chemotherapy recipients.

This abstract lists numerous dermatological side effects and reactions associated with various medications but reports no new research findings.

This study suggests that combining bendamustine with tucidinostat may improve survival in patients with relapsed or refractory adult T-cell leukemia/lymphoma, highlighting its potential for clinical investigation.

In this study, tebentafusp-tebn improved overall survival in patients with metastatic uveal melanoma compared to standard therapies, despite higher rates of significant adverse events.

This study found that N-acetylcysteine effectively prevented cyclophosphamide-induced alopecia in rats, and ImuVert plus N-acetylcysteine prevented alopecia from a cyclophosphamide-cytarabine combination.

In patients undergoing treatment with capecitabine for colon cancer and metastatic breast cancer, this study observed that hand-foot syndrome occurred more frequently than with intravenous 5-FU, but other side effects were less common.

This study found that a chemotherapy regimen combining CMFVP and ACP treatments for unresectable metastatic breast cancer yielded a 66.7% overall response rate, with premenopausal women responding more favorably than postmenopausal women.

This review discusses the side effects associated with ovarian cancer treatment and highlights the need for tools to assess, prevent, and manage these effects; it reports no clinical results.

The congress highlighted new gene therapy techniques and cell transplantation methods for treating diseases.

The document concludes that scalp cooling and treatments like minoxidil can help manage hair loss from cancer therapy.

This study identified potential new adverse drug reaction signals for erlotinib, used in lung and pancreatic cancer treatment, by analyzing a large dataset of case reports, indicating further clinical studies are necessary to confirm these findings.

This study reported that Sintilimab combined with chemotherapy may improve outcomes in advanced NSCLC patients but carries a higher risk of certain side effects, including hypothyroidism.

This case report discusses how trichomegaly, an adverse effect of the cancer therapy drug erlotinib, might serve as a marker of positive tumor response and potentially aid in treating madarosis.

This paper discusses the diagnostic challenges and treatment options for folliculotropic mycosis fungoides, emphasizing the differing prognoses between its indolent and aggressive subtypes and reporting no new clinical results.

This article describes how recognizing distinct trichoscopic features aids in diagnosing various dermatological conditions and hair loss, but it reports no new clinical findings.

S-1 treatment led to a complete response in pancreatic cancer with manageable side effects.

This study found that while the carboplatin-paclitaxel regimen for advanced lung cancer is more affordable than newer treatments and maintains a good performance status, it significantly increases risks of alopecia and peripheral neuropathy.

This study found that Cinobufacin combined with chemotherapy improved clinical outcomes in breast cancer patients and reduced certain side effects compared to chemotherapy alone.

This report documents a case where a man survived sub-acute toxicity from an overdose of the anticancer drug UFT due to effective treatment with antibiotics and granulocyte colony-stimulating factor.

This chapter reviews studies on the side effects of cytostatics and immunosuppressive drugs, detailing various toxicities such as cardiovascular, pulmonary, and neurotoxicity, but provides no new clinical results.

The drug TGU was ineffective against small cell lung cancer and caused significant bone marrow suppression.

A cancer patient died from a severe skin reaction after taking the drug cetuximab.

This study tested a folate-conjugate drug delivery system and found its cytotoxicity depends on whether the treated cells overexpress folate receptors, suggesting potential for targeted chemotherapy.

This study found that glibenclamide exhibited a cytostatic effect on MDA-MB-231 breast cancer cells, potentially mediated through K ATP channels, and enhanced the antiproliferative impact of doxorubicin.

In this study, a combination of irinotecan and cetuximab showed varied response rates in metastatic colorectal cancer patients, with manageable skin toxicity that improved quality of life when treated collaboratively by oncology and dermatology teams.

This study found that sacituzumab govitecan improved health-related quality of life in most areas for patients with HR+/HER2− metastatic breast cancer compared to chemotherapy, except for increased diarrhea, supporting its use as a treatment option.

This study observed that MIRV improved gastrointestinal symptoms and other quality of life measures in patients with platinum-resistant ovarian cancer compared to chemotherapy.

This review explores various theories of colorectal cancer stem cell biology and highlights the need for better identification and targeting of these cells to advance treatment strategies, but reports no new clinical findings.

This study suggests that increased use of anticancer drugs from 2004 to 2008 has led to higher environmental release, necessitating expanded monitoring and research on their ecotoxicological impacts.

This review discusses various therapeutic strategies targeting platelet-derived growth factor signaling in diseases like cancer and atherosclerosis, and evaluates existing treatments without presenting new clinical data.